BiotechTube

Dupilumab + Placebo matching dupilumab + AR101

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peanut Allergy

Conditions

Peanut Allergy

Trial Timeline

Oct 3, 2018 → Jul 23, 2021

NCT ID
NCT03682770

About Dupilumab + Placebo matching dupilumab + AR101

Dupilumab + Placebo matching dupilumab + AR101 is a phase 2 stage product being developed by Sanofi for Peanut Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT03682770. Target conditions include Peanut Allergy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03682770Phase 2Completed

Competing Products

20 competing products in Peanut Allergy

See all competitors
ProductCompanyStageHype Score
ASP0892 Intradermal + ASP0892 Intramuscular + Placebo Intradermal + Placebo IntramuscularAstellas PharmaPhase 1
33
ASP0892 + PlaceboAstellas PharmaPhase 1
33
ligelizumab + PlaceboNovartisPhase 3
77
remibrutinib + placeboNovartisPhase 2
52
QGE031 + PlaceboNovartisPhase 2
52
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3
77
DupilumabSanofiPhase 2
51
Etokimab + PlaceboAnaptysBioPhase 2
47
DBV712 IHRPDBV TechnologiesPhase 1
28
Epicutaneous Immunotherapy + placebo of peanutDBV TechnologiesPhase 2
47
Viaskin Peanut 250 mcg + PlaceboDBV TechnologiesPhase 3
72
Viaskin PeanutDBV TechnologiesPre-clinical
18
Viaskin Peanut 50 mcg + Viaskin Peanut 100 mcg + Viaskin Peanut 250 mcg + Viaskin PlaceboDBV TechnologiesPhase 2
47
DBV712 250 mcgDBV TechnologiesPhase 3
72
Whole peanut extract + Placebo formulationDBV TechnologiesPhase 1
28
Viaskin Peanut 250 mcgDBV TechnologiesPhase 2
47
DBV712 + DBV712DBV TechnologiesPhase 3
72
Part A Viaskin Peanut 250 mcg + Part A Viaskin Peanut 100 mcg + Part A Placebo + Part B Viaskin Peanut 250 mcg + Part B PlaceboDBV TechnologiesPhase 3
72
Viaskin Peanut 250mcg + PlaceboDBV TechnologiesPhase 3
72
Viaskin Peanut 250µgDBV TechnologiesPhase 3
72

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84